Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 16.76 EUR Market Closed
Market Cap: 490.1m EUR
Have any thoughts about
Medincell SA?
Write Note

Medincell SA
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Medincell SA
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Medincell SA
PAR:MEDCL
Operating Expenses
-€27.6m
CAGR 3-Years
-7%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Sanofi SA
PAR:SAN
Operating Expenses
-€28.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Operating Expenses
-€2.2B
CAGR 3-Years
-16%
CAGR 5-Years
-9%
CAGR 10-Years
-12%
Vetoquinol SA
PAR:VETO
Operating Expenses
-€197.6m
CAGR 3-Years
-5%
CAGR 5-Years
-9%
CAGR 10-Years
-7%
Virbac SA
PAR:VIRP
Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
Operating Expenses
-€321.5m
CAGR 3-Years
-1%
CAGR 5-Years
3%
CAGR 10-Years
1%
No Stocks Found

Medincell SA
Glance View

Market Cap
487.2m EUR
Industry
Pharmaceuticals

MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.

MEDCL Intrinsic Value
21.71 EUR
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Medincell SA's Operating Expenses?
Operating Expenses
-27.6m EUR

Based on the financial report for Mar 31, 2024, Medincell SA's Operating Expenses amounts to -27.6m EUR.

What is Medincell SA's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-12%

Over the last year, the Operating Expenses growth was 9%. The average annual Operating Expenses growth rates for Medincell SA have been -7% over the past three years , -12% over the past five years .

Back to Top